A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjogren's Syndrome

On trial facts alone, this looks somewhat more likely to miss than hit. It is a Phase 2 study in Sjogren's syndrome, a heterogeneous autoimmune disease where efficacy signals are often difficult to separate from noise. The primary endpoint structure is demanding: ESSDAI change at Week 48 in one population and ESSPRI change at Week 24 in another population. That creates extra failure modes through multiple analysis populations, possible endpoint discordance, and more complex interpretation even if one readout looks better than the other. ESSDAI is clinically meaningful but can be variable in mid-stage studies, while ESSPRI is patient reported and therefore more placebo-sensitive. The 48-week follow-up also increases operational risk through dropout, missing data, and adherence issues. Positives are that the study is randomized against placebo, uses established disease measures, and is run by a capable large sponsor, which supports execution quality. Still, without any supportive prior efficacy signal in the provided facts, the base rate for a clearly positive Phase 2 autoimmune readout appears below 50%.

HZN-1116/AMG 329 is a first-in-class anti-FLT3L antibody with strong preclinical rationale: elevated FLT3L in SS patients correlates with disease activity, and mouse model showed significant reduction in DCs, T cell activation, and salivary gland inflammation. Phase 1 showed clean safety and robust PD (>80% pDC reduction). However, Sjögren's is historically one of the hardest autoimmune indications, with most of ~30 RCTs failing. The trial has dual primary endpoints across two populations: ESSDAI (Week 48, systemic) and ESSPRI (Week 24, symptoms). Hitting both is challenging; ESSPRI improvement has eluded most drugs even when ESSDAI improves. While recent trials (dazodalibep, iscalimab, ianalumab) show the field is improving, this is a novel mechanism without prior clinical efficacy data in any indication. Phase 2 base rates in autoimmune indications run ~30-35%, and the dual-endpoint structure lowers success probability. I estimate ~35% YES probability.

This is a Phase 2 trial for HZN-1116 in Sjogren's Syndrome, an autoimmune disease with historically challenging drug development. Amgen is the sponsor, providing some credibility. The study uses validated EULAR endpoints (ESSDAI and ESSPRI), which is methodologically sound. However, Phase 2 trials typically have success rates around 30-40% for efficacy, and Sjogren's is a difficult indication with limited treatment options. The study has two populations with different endpoints and timeframes (Week 24 and Week 48), adding complexity. With no prior public data on HZN-1116 and the trial just completing primary completion (-14 days), there is insufficient information to estimate high confidence. The baseline probability for a positive Phase 2 outcome in autoimmune diseases is modest.

This Phase 2 trial for Sjogren's syndrome has significant execution and endpoint risk. The dual primary endpoints (ESSDAI at 48 weeks and ESSPRI at 24 weeks) in separate populations complicate the success criteria. Sjogren's is a heterogeneous autoimmune disease with high placebo effects, making it difficult to demonstrate clear drug efficacy in a mid-size Phase 2. The sponsor, Amgen, is capable, but the mechanism of HZN-1116 is not specified, limiting assessment of biological plausibility. The primary completion date has passed (-14 days), increasing near-term disclosure risk, but the 'Active Not Recruiting' status suggests data is being analyzed, not that results are known. Overall, the intrinsic odds appear below even.

This Phase 2 trial evaluates HZN-1116 vs placebo in Sjogren's Syndrome, a difficult autoimmune indication with no approved disease-modifying drugs. Primary endpoints are changes in ESSDAI at week 48 for Population 1 (physician-assessed disease activity) and ESSPRI at week 24 for Population 2 (patient-reported symptoms). These are standard, validated endpoints, but Sjogren's trials face challenges: heterogeneous patient populations, high placebo responses (especially in ESSPRI), and need for clinically meaningful improvements. No prior efficacy data for HZN-1116 is provided, indicating this is likely the first pivotal efficacy read. Amgen's sponsorship suggests strong operational execution and low risk of poor data quality or delays. With primary completion just 14 days past, results imminent with minimal disclosure risk. However, historical Phase 2 success in Sjogren's is low (~25-35%), due to past failures in similar trials. Dual endpoints increase bar for positivity. Intrinsic P(YES) = 35%.

This Phase 2 trial for HZN-1116 in Sjogren's syndrome faces significant risk. The primary endpoint, ESSDAI (a systemic disease activity index), is historically difficult to move in Sjogren's. The trial includes a co-primary endpoint of patient-reported symptoms (ESSPRI). HZN-1116 (anti-CD40L) carries immunosuppression risks. The primary completion was March 2026, but the study status is 'Active, not recruiting' with a primary completion date in the past. This suggests potential delays or issues. Given the high failure rate in Sjogren's and the mechanism's unproven efficacy in this indication, the probability of a clearly positive outcome is low.

This Phase 2 Sjogren's trial completed primary completion 14 days ago with no results disclosed, creating information asymmetry risk. The dual-primary endpoint structure (ESSDAI at 48 weeks for Population #1, ESSPRI at 24 weeks for Population #2) complicates success definition and may enable selective reporting. Sjogren's syndrome has a poor track record for drug development with high placebo response rates and subjective endpoints. Amgen's operational execution is solid, but the indication itself carries inherent risk. The 'Active Not Recruiting' status suggests database lock or analysis ongoing. No prior Phase 1 data for HZN-1116 is disclosed in public sources, raising uncertainty about mechanism validation. Disclosure risk is elevated given the completion date has passed without announcement.

HZN-1116 (AMG 329) is an anti-FLT3-L monoclonal antibody that potently reduces plasmacytoid and conventional dendritic cells. This directly neutralizes the core interferon-driven pathogenesis of Sjögren's syndrome, providing exceptionally strong biological plausibility. The Phase 2 trial utilizes a highly de-risked, split-cohort design: separating patients with high systemic disease activity (assessed by ESSDAI) from those with moderate-to-severe subjective symptoms (assessed by ESSPRI). Horizon Therapeutics successfully pioneered this exact identical design for dazodalibep's unequivocally positive Phase 2 trial in Sjögren's. By enriching each population for the specific endpoint being measured, the risk of a diluted effect size—which has plagued historical Sjögren's trials—is substantially minimized. Furthermore, striking anecdotal reports from an unblinded or highly responsive trial participant surfaced in early 2025, detailing profound and rapid improvements in Schirmer's tests and salivary flow. This signals that the drug is highly active with a potentially massive clinical effect size in some patients. The primary completion date recently passed in mid-March 2026, and topline data should be imminent, likely coinciding with Amgen's upcoming Q1 2026 earnings. Considering the validated trial design strategy inherited from Horizon, the highly targeted mechanism of action, and real-world hints of profound efficacy, the intrinsic probability of a positive outcome significantly exceeds the market's coin-flip pricing.

The trial is in Phase 2, investigating HZN-1116 for Sjogren's Syndrome. The primary endpoints include change from baseline in EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) and EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI). Given that it's a Phase 2 study with a relatively small sample size and the primary completion date was recently passed, there is inherent uncertainty. The intervention's success heavily depends on the drug's efficacy and safety profile. Without access to detailed interim results or comparative data, a conservative estimate of 40% probability of positive results seems reasonable.